肺炎支原体(Mycoplasma Pneumoniae,MP)是我国儿童社区获得性肺炎中最常见的病原体之一[1,2]。肺炎支原体肺炎(MP Pneumonia,MPP)占小儿肺炎的10%~30%。但重症肺炎支原体肺炎(Severe MPP,SMPP)则表现为对常规大环内酯类抗生素等治疗效果差,病情进展快,甚至会在发病后不久即出现并发症、后遗症等。本文就目前SMPP的诊治研究新进展 Mycoplasma pneumoniae (MP) is one of the most common pathogens in children’s community-acquired pneumonia [1,2]. Mycoplasma pneumoniae (MP Pneumonia, MPP) accounted for 10% to 30% of children with pneumonia. However, Severe Mycoplasma Pneumonia (Severe MPP, SMPP) is manifested as conventional macrolide antibiotics and other poor treatment, rapid progression, and even soon after the onset of complications, sequelae and so on. This article on the current SMPP diagnosis and treatment of new research progress